Search clinical trials for: Tiotropium fenoterol

Total 436 results

Boehringer Ingelheim

Completed

Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Pulmonary Disease, Chronic Obstructive

Germany, Italy, Switzerland, South Africa
Fraunhofer-Institute of Toxicology and Experimental...
Boehringer Ingelheim

Completed

Effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on Cardiac Function in Hyperinflated COPD Subjects

Chronic Obstructive Pulmonary Disease

Germany
Mylan Inc.
Theravance Biopharma

Completed

A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Boehringer Ingelheim

Completed

Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients

Pulmonary Disease, Chronic Obstructive

Japan
3M
Quotient Clinical

Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Two Reference Products

Healthy

United Kingdom
Boehringer Ingelheim

Completed

The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy Subjects

Renal Insufficiency
Boehringer Ingelheim
Pfizer

Completed

Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Czech Republic, Germany, Greece, Netherlands, Portugal, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

RUSSE / Russian Spiriva® Safety & Efficacy Study

COPD

Russian Federation
Novartis Pharmaceuticals

Completed

Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Japan
Boehringer Ingelheim
Pfizer

Completed

Tiotropium In Exercise

Pulmonary Disease, Chronic Obstructive | Exercise

United States, Argentina, Brazil, Canada, Germany, Italy, Portugal, Russian Federation, Spain, Taiwan, Ukraine
Novartis Pharmaceuticals

Completed

Exacerbation Study (INVIGORATE)

Chronic Obstructive Pulmonary Disease

Germany, Belgium, Colombia, Romania, South Africa, Italy, Hungary, Taiwan, Turkey, Switzerland, Australia, France, Israel, Sweden, China, Thailand, Estonia, Netherlands, Russian Federation, Slovakia, Spain, Argentina, Lithuania, Austria, Cana... and more
Boehringer Ingelheim

Completed

An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent Asthma

Asthma

Germany, Denmark, Netherlands
Laval University
Boehringer Ingelheim

Completed

Effects of Tiotropium on Walking Capacity in Patients With COPD

Chronic Obstructive Pulmonary Disease

Canada
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

Germany
Boehringer Ingelheim

Completed

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Germany, Netherlands, Norway
Boehringer Ingelheim

Completed

Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease

Pulmonary Disease, Chronic Obstructive
National Institute of Respiratory Diseases, Mexico

Completed

Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure (EMERALD2)

COPD

Mexico
3M

Completed

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product

Healthy

United Kingdom
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Tiotropium Easyhaler and Spiriva Handihaler

Healthy Subjects

Finland
Boehringer Ingelheim

Completed

Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients

Pulmonary Disease, Chronic Obstructive

Italy
Theron Pharmaceuticals, Inc.

Completed

Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics

Asthma

United States
Boehringer Ingelheim

Completed

Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Spiriva® Assessment of FEV1 (SAFE)

Pulmonary Disease, Chronic Obstructive

Canada
AstraZeneca

Completed

A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients

COPD

Poland, Sweden
Novo Nordisk A/S

Completed

Observational Study on Safety of Self-titration of Once Daily Levemir® (SOLVE™)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Huashan Hospital

Unknown

Efficiency of Budesonide Combined With Formoterol and Tiotropium in the Treatment of Acute Exacerbation of ACO

Asthma-COPD Overlap
Boehringer Ingelheim

Completed

Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma

Asthma
Boehringer Ingelheim

Completed

Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines

Pulmonary Disease, Chronic Obstructive

Austria
Boehringer Ingelheim

Completed

A Prescription-Event Monitoring (PEM) Study of Tiotropium

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD

Pulmonary Disease, Chronic Obstructive

France
Boehringer Ingelheim

Completed

Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Tiotropium (Spiriva) Rehabilitation Study

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Mel Shiuann-Sheng Lee
Novartis

Completed

Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy

Functional Outcomes | Prevention of BMD Loss After THR | Serum Markers of Bone Turnover

Taiwan
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

Asthma

United States, Brazil, China, Guatemala, India, Japan, Latvia, Mexico, Peru, Poland, Russian Federation
Boehringer Ingelheim

Completed

Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease

Pulmonary Disease, Chronic Obstructive
Yonsei University

Not yet recruiting

Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE]

Chronic Obstructive Pulmonary Disease

Korea, Republic of
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Czech Republic, Germany, Hungary, Poland
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

Asthma

United States, Belgium, Finland, Germany, Korea, Republic of, Latvia, Lithuania, Malaysia, Netherlands, Philippines, Ukraine
Boehringer Ingelheim
Pfizer

Completed

A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma

Asthma

Germany, Hungary, Latvia, Lithuania, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Tiotropium / Respimat One-Year Study

Pulmonary Disease, Chronic Obstructive

Austria, Canada, Spain, United States, Finland, Italy, Russian Federation, United Kingdom, New Zealand, Australia, France, Greece, Ireland, Netherlands, South Africa
Boehringer Ingelheim

Completed

Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease (LaCrossE)

Chronic Obstructive Pulmonary Disease

Sweden
Boehringer Ingelheim

Completed

12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)

Pulmonary Disease, Chronic Obstructive

Sweden

3

Subscribe